Status:
COMPLETED
A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Fungal Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of ertapenem sodium as initial therapy for the treatment of complicated urinary tract infections, including pyelonephriti...
Eligibility Criteria
Inclusion
- Patient has a low white cell count (less than 500/mm3) for at least 96 hours
- Patient is indian and is greater than 18 years of age
- Patient received chemotherapy for blood disorders and blood cancers
Exclusion
- Patient has an invasive fungal infection
- Patient has a bacterial infection that is not controlled
- Patient has allergy to the class of antifungals of study drug
- Patient is not expected to survive at least 5 days
- Patient is pregnant or breast-feeding
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00379964
Start Date
June 1 2005
End Date
May 1 2006
Last Update
February 23 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.